The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 13, Issue 11, Pages 1257-1269
Publisher
Future Medicine Ltd
Online
2012-08-24
DOI
10.2217/pgs.12.102
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients
- (2012) Annika Dufour et al. ANNALS OF HEMATOLOGY
- PPARα and PPARγ regulate the nucleoside transporter hENT1
- (2012) Trinidad D. Montero et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management
- (2011) Elihu H. Estey AMERICAN JOURNAL OF HEMATOLOGY
- DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications
- (2011) H.-A. Hou et al. BLOOD
- Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia
- (2011) J. E. Karp et al. BLOOD
- FLT3/ITD AML and the law of unintended consequences
- (2011) M. Levis BLOOD
- Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia
- (2011) Sang Hyuk Park et al. LEUKEMIA RESEARCH
- Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing
- (2010) Elisa Giovannetti et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2010) Guido Marcucci et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
- (2010) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Human placental glutathione S-transferase activity and polycyclic aromatic hydrocarbon DNA adducts as biomarkers for environmental oxidative stress in placentas from pregnant women living in radioactivity- and chemically-polluted regions
- (2010) Maria Yu. Obolenskaya et al. TOXICOLOGY LETTERS
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
- (2009) J.-L. Harousseau et al. BLOOD
- Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival
- (2009) Y. Guo et al. CLINICAL CANCER RESEARCH
- Cytidine Deaminase Residual Activity in Serum Is a Predictive Marker of Early Severe Toxicities in Adults After Gemcitabine-Based Chemotherapies
- (2009) Joseph Ciccolini et al. JOURNAL OF CLINICAL ONCOLOGY
- SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival
- (2009) U Mahlknecht et al. LEUKEMIA
- Frequency and development of CNS involvement in Chinese children with hemophagocytic lymphohistiocytosis
- (2009) Shuang Yang et al. PEDIATRIC BLOOD & CANCER
- Genetic factors influencing cytarabine therapy
- (2009) Jatinder K Lamba PHARMACOGENOMICS
- Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
- (2008) J. E. Karp et al. BLOOD
- Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
- (2008) M. A. Sanz et al. BLOOD
- Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors
- (2008) C Lemos et al. BRITISH JOURNAL OF CANCER
- Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia
- (2008) Deepika Bhatla et al. BRITISH JOURNAL OF HAEMATOLOGY
- Farnesyltransferase Inhibitors: A Detailed Chemical View on an Elusive Biological Problem
- (2008) Sergio Sousa et al. CURRENT MEDICINAL CHEMISTRY
- Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
- (2008) Peter Paschka et al. JOURNAL OF CLINICAL ONCOLOGY
- Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration
- (2008) B Chapuy et al. LEUKEMIA
- Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia
- (2008) M T Voso et al. LEUKEMIA
- A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders
- (2007) Judith E. Karp et al. LEUKEMIA RESEARCH
- SKAP55 modulates T cell antigen receptor-induced activation of the Ras–Erk–AP1 pathway by binding RasGRP1
- (2007) Karena A. Kosco et al. MOLECULAR IMMUNOLOGY
- ABC multidrug transporters: structure, function and role in chemoresistance
- (2007) Frances J Sharom PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started